Drug Profile
PTX 200
Alternative Names: PTX-200Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Phytrix
- Class Antiparkinsonians; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 01 Feb 2011 No development reported - Phase-I/II for Parkinson's disease in United Kingdom (unspecified route)
- 19 Dec 2005 PTX 200 is available for licensing (http://phytrix.com)
- 19 Dec 2005 Phase-I/II clinical trials in Parkinson's disease in United Kingdom (unspecified route)